AMPE:NYE-Ampio Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.87

Change

+0.03 (+3.12)%

Market Cap

USD 0.16B

Volume

1.98M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Company Website : http://www.ampiopharma.com

Address : 373 Inverness Parkway, Englewood, CO, United States, 80112

Employees : 23

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.80

52 Week High : 1.39

Short Ratio : 17.95

52 Week Low : 0.35

Shorted Shares : 19,594,530

200 Day Moving Average : 0.76

Shorted Shares Previous Month : 18,661,068

50 Day Moving Average : 0.83

Shares Held By Insiders : 75.95999999999999%

Short Percentage : 11.00%

Shares Held by Institutions : 12.01%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.22 (+0.33%)

 USD152.06B 24.03 2.70
BHVN Biohaven Pharmaceutical Holdin..

-0.52 (-0.58%)

 USD5.40B N/A N/A
ADCT ADC Therapeutics SA

-0.05 (-0.14%)

 USD2.74B -99,999.99 N/A
ZYME Zymeworks Inc

+0.79 (+1.65%)

 USD2.19B 300.20 N/A
MYOV Myovant Sciences Ltd

+0.39 (+1.82%)

 USD1.94B N/A N/A
RCUS Arcus Biosciences, Inc

-1.00 (-3.94%)

 USD1.65B N/A N/A
CVM CEL-SCI Corporation

+0.21 (+1.71%)

 USD0.47B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

-0.24 (-1.15%)

 USD0.33B N/A N/A
IBIO iBio, Inc

-0.01 (-0.68%)

 USD0.27B N/A N/A

ETFs Containing AMPE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.00% 75% C 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 75% C 93% A
Trailing 12 Months  
Capital Gain 93.33% 85% B 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.33% 85% B 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.64% N/A N/A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.64% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 37.88% N/A N/A 13% F
Risk Adjusted Return 41.30% N/A N/A 57% F
Market Capitalization 0.16B 59% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.87 22% F 28% F
Price/Book Ratio 14.85 22% F 5% F
Price / Cash Flow Ratio -10.15 62% D- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -165.48% 21% F 2% F
Return on Invested Capital -318.11% 14% F 0% N/A
Return on Assets -75.65% 18% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 16.48 10% F 2% F
Short Percent 10.52% 15% F 34% F
Beta 1.80 52% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.